Sumitomo Chemical India
- Market Cap
- ₹17,006 Cr
- P/E
- 30.45
Key Fundamentals
SmallcapFertilizers & AgrochemicalsChemicalsPrice-based figures as of · EPS basis: Standalone · TTM
- ROCE
- 23.50%
- Debt to Equity
- 0.01
- EPS (TTM)
- ₹11.19
- Book Value
- ₹73.97
- Market Cap
- ₹17,006 Cr
- P/E (TTM)
- 30.45
- P/B
- 4.61
- ROE
- 17.60%
- Dividend Yield
- 0.38%
- EBITDA
- ₹818 Cr
- 52W High
- ₹572.05
- 52W Low
- ₹310.85
- Day Range
- ₹338.00 – ₹343.85
- Volume
- 2,06,335
Peer Comparison
Commodities › Fertilizers & Agrochemicals › Pesticides & Agrochemicals
| 571.95 | 25.56 | 48,282 | 1.39 | 1.09% | 5.64% | 10.10% | 52,645 | 2,163 | |
| 1,597.40 | 27.60 | 24,235 | 2.12 | 0.92% | 11.20% | 15.00% | 6,345 | 877 | |
| 340.70 | 30.45 | 17,006 | 4.61 | 0.39% | 17.60% | 23.50% | 3,168 | 559 | |
| 3,356.20 | 20.23 | 15,083 | 4.74 | 2.69% | 23.70% | 29.10% | 5,293 | 746 | |
| 660.70 | 9.26 | 5,961 | 1.83 | 2.15% | 23.20% | 30.20% | 5,479 | 644 | |
| 909.90 | 14.40 | 4,056 | 2.32 | 0.21% | 18.50% | 23.80% | 2,013 | 283 | |
| 186.96 | 18.46 | 3,636 | 1.66 | 1.58% | 10.20% | 14.10% | 2,959 | 197 | |
| Median 7 companies | 660.70 | 20.23 | 15,083 | 2.12 | 1.09% | 17.60% | 23.50% | 5,293 | 644 |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 66
- Strong
- Returns, margins, earnings quality 22% weight
- Valuation
- 38
- Weak
- Cheap vs sector & own history 24% weight
- Growth
- 13
- Poor
- Sales & profit trajectory 9% weight
- Financial Health
- 89
- Strong
- Solvency, leverage, coverage 9% weight
- Momentum
- 11
- Poor
- Trend strength, vol-adjusted 12% weight
- Ownership
- 56
- Good
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
2- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 34.5%
Weaknesses
1- The company has delivered a poor sales growth of 3.81% over past five years.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bearish | 10 | 5 | 4 |
| Oscillators | Bullish | 1 | 5 | 3 |
| Moving Averages | Strong Bearish | 9 | 0 | 1 |
Oscillators
Bullish
Overall
Strong Bearish
Moving Averages
Strong Bearish
Key readings
- RSI (14)
- 40.30
- Neutral
- MACD (12,26,9)
- −13.93
- Bullish
- SMA (50)
- 392.39
- Bearish
- SMA (200)
- 443.24
- Bearish
As of
Analyst Rating
8 of 9 analysts rate Buy, 1 Hold, 0 Sell.
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.
Revenue
| 10Y | +15.97% |
|---|---|
| 5Y | +3.81% |
| 3Y | −3.19% |
| 1Y | +3.11% |
| TTM | −2.49% |
Net profit
| 10Y | +23.65% |
|---|---|
| 5Y | +9.50% |
| 3Y | +2.58% |
| 1Y | +8.17% |
| TTM | +3.52% |
Operating cash flow
| 10Y | +23.89% |
|---|---|
| 5Y | +0.88% |
| 3Y | +4.43% |
| 1Y | −3.28% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | +8.61 pp |
|---|---|
| 5Y | +2.44 pp |
| 3Y | +1.87 pp |
| 1Y | +0.74 pp |
| TTM | +0.26 pp |
Revenue by year
| Mar 2017 | ₹799 Cr |
|---|---|
| Mar 2018 | ₹1,911 Cr |
| Mar 2019 | ₹2,223 Cr |
| Mar 2020 | ₹2,423 Cr |
| Mar 2021 | ₹2,643 Cr |
| Mar 2022 | ₹3,060 Cr |
| Mar 2023 | ₹3,511 Cr |
| Mar 2024 | ₹2,833 Cr |
| Mar 2025 | ₹3,090 Cr |
| Mar 2026 | ₹3,186 Cr |
Net profit by year
| Mar 2017 | ₹62.00 Cr |
|---|---|
| Mar 2018 | ₹145 Cr |
| Mar 2019 | ₹167 Cr |
| Mar 2020 | ₹206 Cr |
| Mar 2021 | ₹345 Cr |
| Mar 2022 | ₹434 Cr |
| Mar 2023 | ₹503 Cr |
| Mar 2024 | ₹370 Cr |
| Mar 2025 | ₹502 Cr |
| Mar 2026 | ₹543 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
Sumitomo Chemical India Ltd trades at ₹342.4 as of 2026-11-17 with a market cap of ₹17,091 Cr, a PE of 30.6x, and a near-zero debt-to-equity ratio of 0.02. The company has a strong long-term profit compounding record of 24% over 10 years, but recent sales and profit growth have decelerated sharply, with TTM sales declining 3% and TTM profit growing just 2%.
- The company is virtually debt-free with a debt-to-equity ratio of just 0.02, providing significant financial flexibility and resilience through economic cycles.
- 10-year compounded profit growth of 24% demonstrates a strong long-term earnings trajectory and sustained business model strength.
- 10-year compounded sales growth of 16% reflects a solid track record of revenue expansion over the longer term.
- ROCE of 20.98% indicates efficient capital deployment, suggesting the business generates healthy returns on invested capital.
- ROE has been consistently strong, averaging 20% over 5 years and 20% over 10 years, indicating reliable shareholder value creation.
- The company maintains a healthy dividend payout ratio of 34.5%, balancing reinvestment with shareholder returns.
- 5-year compounded profit growth of 10% shows the business has been able to grow earnings at a reasonable pace even through recent challenging periods.
- TTM sales growth is negative at -3%, and 3-year compounded sales growth is also -3%, indicating a sustained revenue contraction trend.
- TTM profit growth has decelerated to just 2%, a sharp slowdown from the 10-year compounded profit growth of 24%.
- The stock has declined 25% over the past 1 year and delivered a negative 4% CAGR over 3 years, significantly underperforming for investors.
- PE of 30.6x is elevated relative to the TTM EPS growth of just 2%, implying the valuation is pricing in a recovery that has yet to materialize.
- 5-year compounded sales growth of only 4% and poor past five-year sales growth of 3.81% highlight structural challenges in scaling revenues.
- Dividend yield of 0.38% is minimal and offers limited income cushion to investors during a period of capital depreciation.
- 5-year stock CAGR of -2% indicates that the market has not rewarded the company's operational performance over a medium-term horizon.
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: Sumitomo Chemical India delivered a weak Q2FY27 with declines across profit, revenue, and margins. The 297 bps EBITDA margin compression is the most notable concern, pointing to either input cost pressure or weaker pricing power. The global parent's earnings decline adds to the cautious picture. The trend is deteriorating and investors will watch for signs of margin recovery and top-line stabilization in coming quarters.
- Q2 net profit falls 11% YoY Nov 02
Sumitomo Chemical India reported Q2FY27 net profit of ₹157.4 crore, down 11% YoY, signaling earnings pressure.
- EBITDA margin compresses 297 bps Nov 02
EBITDA margin contracted by 297 basis points to 20.5% in Q2FY27, reflecting cost or pricing headwinds.
- Revenue declines 2% YoY Nov 02
Q2FY27 revenue came in at ₹907.3 crore, a 2% YoY decline indicating soft top-line momentum.
Quarterly Results
₹ Cr| Particulars | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 903 | 540 | 664 | 832 | 971 | 622 | 665 | 1,048 | 914 | 552 | 671 | 1,054 | 891 |
| Expenses | 715 | 474 | 526 | 670 | 729 | 521 | 548 | 828 | 697 | 456 | 539 | 819 | 708 |
| Operating Profit | 188 | 66 | 139 | 162 | 242 | 101 | 117 | 220 | 217 | 96 | 133 | 235 | 183 |
| OPM % | 21% | 12% | 21% | 19% | 25% | 16% | 18% | 21% | 24% | 17% | 20% | 22% | 21% |
| Other Income | 25 | 27 | 27 | 26 | 31 | 31 | 31 | 39 | 39 | 36.82 | 32 | 74 | 43 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 |
| Depreciation | 16 | 16 | 16 | 14 | 15 | 18 | 16 | 15 | 16 | 16 | 16 | 16 | 16 |
| Exceptional Items | — | — | — | — | — | — | — | — | — | −15.19 | — | — | — |
| PBT | 196 | 76 | 149 | 173 | 257 | 113 | 132 | 242 | 238 | 100 | 147 | 291 | 209 |
| Tax % | 27% | 27% | 26% | 26% | 26% | 25% | 25% | 26% | 25% | 25% | 25% | 26% | 25% |
| Net Profit | 144 | 55 | 109 | 128 | 191 | 84 | 98 | 180 | 178 | 75 | 111 | 217 | 156 |
| EPS (₹) | 2.88 | 1.10 | 2.19 | 2.57 | 3.82 | 1.69 | 1.97 | 3.60 | 3.56 | 1.50 | 2.22 | 4.34 | 3.13 |
| YoY Sales growth | −19 | −28 | 2 | 15 | 8 | 15 | 0 | 26 | −6 | −11 | 1 | 1 | −3 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 671 | 724 | 799 | 1,911 | 2,223 | 2,423 | 2,643 | 3,060 | 3,511 | 2,833 | 3,090 | 3,186 | 3,168 |
| Expenses | 614 | 635 | 698 | 1,691 | 1,932 | 2,088 | 2,155 | 2,458 | 2,843 | 2,358 | 2,467 | 2,520 | 2,522 |
| Operating Profit | 57 | 89 | 101 | 219 | 291 | 335 | 488 | 603 | 668 | 474 | 623 | 666 | 647 |
| OPM % | 8% | 12% | 13% | 11% | 13% | 14% | 18% | 20% | 19% | 17% | 20% | 21% | 20% |
| Other Income | 8 | 26 | 10 | 31 | 0 | 10.84 | 19 | 36 | 45 | 96 | 119 | 146 | 171 |
| Interest | 1 | 1 | 1 | 5 | 5 | 5.51 | 5.56 | 6.17 | 5.39 | 5 | 6 | 7 | 6 |
| Depreciation | 6 | 7 | 7 | 24 | 28 | 41 | 47 | 45 | 52 | 61 | 63 | 63 | 64 |
| Exceptional Items | — | — | — | — | — | −30.89 | — | — | — | — | — | −15.19 | — |
| PBT | 58 | 107 | 103 | 221 | 258 | 267 | 453 | 586 | 655 | 503 | 674 | 727 | 747 |
| Tax % | 40% | 40% | 40% | 34% | 35% | 23% | 24% | 26% | 23% | 27% | 26% | 25% | — |
| Net Profit | 35 | 65 | 62 | 145 | 167 | 206 | 345 | 434 | 503 | 370 | 502 | 543 | 558 |
| EPS (₹) | — | — | — | — | — | 4.12 | 6.92 | 8.69 | 10.09 | 7.41 | 10.06 | 10.88 | 11.19 |
| Div. Payout % | 0% | 0% | 0% | 0% | 38% | 18% | 12% | 12% | 12% | 80% | 12% | 12% | — |
| Sales growth | 6 | 8 | 10 | 139 | 16 | 9 | 9 | 16 | 15 | −19 | 9 | 3 | −3 |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 233 | 233 | 275 | 275 | 275 | 499 | 499 | 499 | 499 | 499 | 499 | 499 | 499 |
| Reserves | −2 | 63 | 360 | 665 | 761 | 710 | 1,029 | 1,425 | 1,881 | 1,941 | 2,397 | 2,885 | 3,193 |
| Borrowings | 0 | 0 | 0 | 10 | 20 | 36 | 33 | 38 | 34 | 25 | 45 | 53 | 46 |
| Other Liabilities | 234 | 280 | 288 | 695 | 791 | 848 | 1,097 | 1,047 | 955 | 822 | 988 | 997 | 1,198 |
| Total Liabilities | 466 | 576 | 922 | 1,644 | 1,846 | 2,093 | 2,658 | 3,009 | 3,368 | 3,287 | 3,930 | 4,434 | 4,936 |
| Fixed Assets | 51 | 52 | 53 | 267 | 279 | 319 | 309 | 390 | 430 | 489 | 482 | 499 | 492 |
| CWIP | 0 | 1 | 7 | 9 | 8 | 10 | 14 | 35 | 71 | 23 | 28 | 20 | 21 |
| Investments | 0 | 0 | 277 | 2 | 1 | 87 | 291 | 357 | 239 | 425 | 601 | 1,226 | 1,433 |
| Other Assets | 415 | 523 | 585 | 1,367 | 1,558 | 1,676 | 2,043 | 2,227 | 2,628 | 2,351 | 2,819 | 2,690 | 2,991 |
| Total Assets | 466 | 576 | 922 | 1,644 | 1,846 | 2,093 | 2,658 | 3,009 | 3,368 | 3,287 | 3,930 | 4,434 | 4,936 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 4 | 52 | −21 | 49 | 75 | 222 | 424 | 223 | 389 | 756 | 458 | 443 |
| Investing | −8 | −5 | −289 | −40 | −35 | −118 | −282 | −281 | −327 | −426 | −405 | −329 |
| Financing | 0 | 0 | 276 | 7 | −65 | −61 | −47 | −63 | −73 | −331 | −65 | −81 |
| Net Cash Flow | −4 | 47 | −34 | 16 | −26 | 43 | 95 | −120 | −10 | −1 | −11 | 33 |
| Free Cash Flow | −6 | 44 | −310 | 6 | 36 | 184 | 382 | 111 | 270 | 695 | 431 | 404 |
| CFO/EBITDA | 44 | 102 | 14 | 60 | 56 | 90 | 109 | 61 | 83 | 187 | 100 | 91 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 83 | 92 | 101 | 105 | 110 | 128 | 117 | 101 | 98 | 91 | 90 | 81 |
| Inventory Days | 135 | 169 | 191 | 202 | 193 | 133 | 185 | 198 | 157 | 135 | 154 | 166 |
| Days Payable | 109 | 132 | 115 | 176 | 136 | 112 | 145 | 110 | 87 | 96 | 107 | 86 |
| Cash Conversion Cycle | 109 | 130 | 177 | 131 | 167 | 150 | 157 | 189 | 168 | 131 | 136 | 161 |
| Working Capital Days | 69 | 79 | 113 | 113 | 116 | 109 | 95 | 127 | 136 | 173 | 183 | 155 |
| ROCE % | 27% | 41% | 22% | 29% | 27% | 26% | 33% | 34% | 30% | 21% | 25% | 23% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Sumitomo Chemical insights
61 extracted metrics across FY11–FY27.
Documents
- Q2 FY27 concall · Oct 2026Transcript PPT Recording
- Q1 FY27 concall · Jul 2026PPT
- Q4 FY26 concall · Jun 2026Transcript PPT
- Q4 FY26 concall · May 2026PPT
- Q3 FY26 concall · Jan 2026PPT
- 29 Apr 2026
- 30 Jan 2025
- 24 Nov 2023
- 29 May 2023
- 3 Mar 2022
- General announcements 19 Oct 2026
- General announcements 19 Oct 2026
- Compliance 6 Oct 2026
Frequently Asked Questions about Sumitomo Chemical India
What does Sumitomo Chemical India Ltd do?
Where is Sumitomo Chemical India Ltd (SUMICHEM) listed?
Which sector does Sumitomo Chemical India Ltd belong to?
What is the market capitalisation of Sumitomo Chemical India Ltd?
What is the PE ratio of Sumitomo Chemical India Ltd?
What is the 52-week high and low of Sumitomo Chemical India Ltd?
Does Sumitomo Chemical India Ltd pay dividends?
What is the Return on Equity (ROE) of Sumitomo Chemical India Ltd?
Company Information
Sumitomo Chemical India Ltd. (SCIL) is one of the leading players in the industry which has a balanced portfolio of technical as well as formulation products along with backward integration for some products. The Company is known for domestic marketing of proprietary products of its Japanese parent -Sumitomo Chemical Company Limited in agrochemicals, animal nutrition, and environmental health business segments. With the integration of Excel Crop Care Limited, the Company now has a strong portfolio of generics in addition to specialty products and a strong combined marketing network. With this integration, the Company has moved up several notches in the pecking order of the Indian crop protection industry. SCIL has also marked its presence in Africa and several other geographies of the world.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/SUMICHEM.md for Sumitomo Chemical India Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.